Around 200 grams of OG kush and 32 ecstasy pills, all worth over Rs.10.96 lakh were seized from the arrested persons: Police ...

Organon is terminating development of its endometriosis drug after the Phase II trial failed to show any benefit. The ELENA ...

Love Island UK Season 12 Episode 24 aired on July 2, 2025. The latest episode of the reality show featured two Islanders ...

Oklahoma Gas and Electric Company (OG&E) is working with OKC Beautiful and RSVP of Central Oklahoma to install garden beds at the Garden Oaks Community Center and Spencer Senior Center this ...

Several of our testers ascribed the Clifton 10 as their long run shoe of choice. Its firm cushioning can handle accruing high mileage—and help your body take the stress. The shoe has Hoka’s ...

Giannis Antetokounmpo remains one of the most dominant forces in basketball—but make no mistake, the Greek Freak is growing ...

Center Jimmy Morrissey has worn No. 67 after signing with the practice squad as a veteran free agent after a three-year tenure with Houston. He previously spent the 2021 season on the practice squad ...

Judas Priest will not be playing on Saturday afternoon when the world’s biggest metal bands descend upon Villa Park in ...

Dumped Love Island 2025 OG Megan Forte Clarke speaks exclusively to heatworld about the Islander who asked her to the ...

Shuntaro Furukawa was asked about how Nintendo is countering the surge in gaming costs and prices, and his answer was simple but honest.

A drug candidate Organon hailed as perhaps its “biggest potential opportunity” has flunked a phase 2 trial, prompting the company to end clinical development of the endometriosis prospect.

Organon will discontinue its OG-6219 clinical-development program, after the investigational candidate failed to meet its primary efficacy endpoint in treating endometriosis-related pain.